You are here

JNJ

3 Big Drugmakers Boosting Huge R&D Budgets

3 Big Drugmakers Boosting Huge R&D Budgets

Motley Fool

Bristol-Myers Squibb

Flag link:

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Motley Fool

inflammatory bowel disease

Flag link:

J&J Acquisition Could Give Stryker a Run for Its Money in Robotics

J&J Acquisition Could Give Stryker a Run for Its Money in Robotics

Medical Devices and Diagnostics Industry

Flag link:

J&J Is Exploring a Sale of Its $2 Billion Sterilization Division

J&J Is Exploring a Sale of Its $2 Billion Sterilization Division

Bloomberg

Flag link:

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Fierce Pharma

Flag link:

A Possible Financial Boost Awaits Thousands Of Out-Of-State Plaintiffs In Risperdal suit

A Possible Financial Boost Awaits Thousands Of Out-Of-State Plaintiffs In Risperdal suit

Forbes

Flag link:

Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows

Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows

Fierce Pharma

Invega Sustenna

Flag link:

J&J gets first-of-its-kind prostate cancer approval

J&J gets first-of-its-kind prostate cancer approval

Biopharma Dive

prostate cancer

Flag link:

J&J strikes potential $1B JAK inhibitor deal with Theravance

J&J strikes potential $1B JAK inhibitor deal with Theravance

Biopharma Dive

drug development

Crohn's Disease

ulcerative colitis

Flag link:

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

JD Supra

Flag link:

How Johnson & Johnson Medical Devices Companies are working with healthcare customers to achieve the goal of value-based care

How Johnson & Johnson Medical Devices Companies are working with healthcare customers to achieve the goal of value-based care

Medical Devices and Diagnostics Industry

value-based care

Flag link:

Johnson & Johnson falls on report that lawsuits could expose potentially damaging documents

Johnson & Johnson falls on report that lawsuits could expose potentially damaging documents

CNBC

Flag link:

Strong data lift profile of J&J's cancer drug apalutamide

Strong data lift profile of J&J's cancer drug apalutamide

Biopharma Dive

prostate cancer

Flag link:

Biopharma in charts: Key takeaways from Q4 earnings

Biopharma in charts: Key takeaways from Q4 earnings

Biopharma Dive

Flag link:

[video]Johnson & Johnson's Earnings Were Solid, but Questions Remain

[video]Johnson & Johnson's Earnings Were Solid, but Questions Remain

Motley Fool

Flag link:

Johnson & Johnson drops out of the race for Pfizer consumer unit, paving the way for GSK, Reckitt

Johnson & Johnson drops out of the race for Pfizer consumer unit, paving the way for GSK, Reckitt

Fierce Pharma

consumer health

Reckitt Benckiser

Flag link:

Why J&J Expects 2018 to be a Growth Year

Why J&J Expects 2018 to be a Growth Year

Medical Devices and Diagnostics Industry

Flag link:

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

Endpoints

Flag link:

Johnson & Johnson logs Q4 beat, misses with 2017 numbers

Johnson & Johnson logs Q4 beat, misses with 2017 numbers

Mass Device

Flag link:

Consortium of Chinese companies tries to acquire J&J’s LifeScan and Calibra Medical ($3-4bn)

Consortium of Chinese companies tries to acquire J&J’s LifeScan and Calibra Medical ($3-4bn)

GoinPharma

Flag link:

Pages